700 Saginaw Drive
Tel: (650) 481-6801
About Revolution Medicines
REVOLUTION Medicines discovers and develops important new medicines for cancer patients by translating frontier oncology targets – proteins that drive the growth of cancers or that control immune responses that can defeat them. The company has a robust pipeline of R&D programs focused on frontier targets, including SHP2 (PTPN11), a tyrosine phosphatase enzyme that regulates cancer growth signaling and the immune response, SHP1 (PTPN6), a second tyrosine phosphatase that regulates multiple arms of the immune response, and 4EBP1, a key regulator of oncogene translation in the PI3K/AKT/mTOR pathway.
Headquartered in Redwood City, Calif. at the intersection of Silicon Valley and the birthplace of biotechnology, REVOLUTION Medicines is a private company financed by top-tier investors through $126 million raised in Preferred Series A & B rounds.
16 articles with Revolution Medicines
REVOLUTION Medicines Closes $100 Million Financing to Advance Pipeline of Novel Therapies Addressing Frontier Targets in RAS-Dependent Cancers
Lead Clinical Candidate Targeting SHP2 Currently in Phase 1/2 Clinical Program for Tumors with Specific Oncogenic Mutations
Bay Area-based Revolution Medicines Inc. secured $100 million in Series C financing that will be used to support the development of the company’s pipeline of drugs that target the RAS pathway, including its lead clinical candidate.
Ginkgo Bioworks Acquires Warp Drive Bio's Genome Mining Platform for Discovery and Development of Novel Classes of Antibiotics
Acquisition expands Ginkgo's biological codebase for organism engineering for the production of natural product pharmaceuticals
REVOLUTION Medicines, Inc., a biotechnology company that translates frontier oncology targets to outsmart cancer, today announced that it will make a presentation at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
REVOLUTION Medicines Acquires Warp Drive Bio to Expand Drug Discovery Portfolio Focused on Frontier Oncology Targets
REVOLUTION Medicines, Inc. and Warp Drive Bio, Inc. announced today that REVOLUTION Medicines is acquiring Warp Drive Bio.
REVOLUTION Medicines Announces First Patient Dosed with RMC-4630 in Phase 1 Clinical Study in Patients with Advanced Solid Tumors
Scientific publication reports preclinical results showing precision oncology opportunity for targeting SHP2 in genetically selected tumors
Sanofi and REVOLUTION Medicines Launch Global Partnership to Develop Potential First-in-Class Targeted Treatments for Multiple Cancers
Preclinical studies of SHP2 inhibitors demonstrated promise across multiple forms of cancer; lead drug candidate expected to start clinical trials in second half of 2018.
In April Bay Area biotech Revolution Medicines completed its pivot from a company focused on antifungal treatments to an oncology business. This morning Revolution’s shift paid off with a development deal worth up to $500 million with Sanofi.
Revolution Medicines Raises Another $56 Million and Completes Pivot from Antifungal to Cancer Com...
4/24/2018Revolution Medicines closed on a Series B financing round worth $56 million. The round was led by Nextech Invest, with participation from Casdin Capital, Schroder Adveq, The Column Group, Third Rock Ventures and undisclosed institutional investors.
REVOLUTION Medicines, Inc. announced it has raised $56 million in a Series B financing to support its ongoing R&D programs and general business activities.
Revolution Medicines Appoints Cancer Leader Dr. Stephen Kelsey As President Of Research And Development
Revolution Medicines Names Academic Co-Founder, Michael Fischbach, Ph.D., And Senior Advisor, Eric Gordon, Ph.D.
Rationally Designed Antifungal Compounds That Evade Resistance Reported In Nature Chemical Biology By Scientific Founder Of Revolution Medicines
Revolution Medicines Appoints Pharmaceutical Commercial Executive Elizabeth McKee Anderson To Board Of Directors